155 related articles for article (PubMed ID: 23239178)
1. Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism.
Hu ZY; Parker RB; Herring VL; Laizure SC
Anal Bioanal Chem; 2013 Feb; 405(5):1695-704. PubMed ID: 23239178
[TBL] [Abstract][Full Text] [Related]
2. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
Laizure SC; Parker RB; Herring VL; Hu ZY
Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
[TBL] [Abstract][Full Text] [Related]
3. Impact of endogenous esterase activity on in vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayers.
Ishiguro N; Kishimoto W; Volz A; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):250-6. PubMed ID: 24212377
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
5. Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation.
Laizure SC; Chen F; Farrar JE; Ali D; Yang B; Parker RB
Drug Metab Pharmacokinet; 2022 Dec; 47():100479. PubMed ID: 36375226
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of LC-MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma.
Nouman EG; Al-Ghobashy MA; Lotfy HM
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():37-45. PubMed ID: 25797721
[TBL] [Abstract][Full Text] [Related]
7. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
Udomnilobol U; Jianmongkol S; Prueksaritanont T
Drug Metab Dispos; 2023 Sep; 51(9):1216-1226. PubMed ID: 37230768
[TBL] [Abstract][Full Text] [Related]
8. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
Blech S; Ebner T; Ludwig-Schwellinger E; Stangier J; Roth W
Drug Metab Dispos; 2008 Feb; 36(2):386-99. PubMed ID: 18006647
[TBL] [Abstract][Full Text] [Related]
9. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta.
Bapat P; Kedar R; Lubetsky A; Matlow JN; Aleksa K; Berger H; Koren G
Obstet Gynecol; 2014 Jun; 123(6):1256-1261. PubMed ID: 24807346
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
11. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
Zhao Y; Hu ZY
Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism.
Wu WN; McKown LA; Reitz AB
Eur J Drug Metab Pharmacokinet; 2006; 31(4):277-83. PubMed ID: 17315539
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluororacil-Induced Gastrointestinal Damage Impairs the Absorption and Anticoagulant Effects of Dabigatran Etexilate.
Tsujii K; Hattori T; Imaoka A; Akiyoshi T; Ohtani H
J Pharm Sci; 2018 May; 107(5):1430-1433. PubMed ID: 29291414
[TBL] [Abstract][Full Text] [Related]
15. Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV correction.
Yang Y; Grubb MF; Luk CE; Humphreys WG; Josephs JL
Rapid Commun Mass Spectrom; 2011 Nov; 25(21):3245-51. PubMed ID: 22006386
[TBL] [Abstract][Full Text] [Related]
16. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
17. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
18. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
Delavenne X; Moracchini J; Laporte S; Mismetti P; Basset T
J Pharm Biomed Anal; 2012 Jan; 58():152-6. PubMed ID: 21996066
[TBL] [Abstract][Full Text] [Related]
19. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine.
Xie Y; Lu Z; Styles IK; Reddiar SB; Phillips ARJ; Windsor JA; Porter CJH; Han S; Trevaskis NL
J Pharm Sci; 2024 Apr; ():. PubMed ID: 38582284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
